We added three high-yielding stocks last month to the Retirement Paycheck portfolio, and they alread...
02/28/2017 6:00 am EST
Aratana Therapeutics (PETX) sold off some 20%as its product Entyce’s rollout will be delayed until the fourth quarter as the company is changing manufacturers.
This does not affect the company’s other two drugs “galliprant” and “nocita” which are just being launched. It should mean less than $10 million in delayed revenues this year from entice.
A $60 million market cap hit was unwarranted and the stock is already starting to recover. I added significantly to my holdings in Aratana on the drop.
Related Articles on STOCKS
I don’t have any idea where the stock market will go over the short term. But I do know that i...
Stefanie Kammerman, The Stock Whisperer, to tell you the Whisper of the Week: FCX, IAU, F in my week...